Physician profile
David William Shoemaker
NPI 1336258433
$2,106.56
in general payments reported to CMS, 2019-2025
13 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $49.33 · 2021: $268 · 2022: $468 · 2023: $305 · 2024: $183 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.96 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $788.95 | 2019-2025 | Tecnis Iol |
| Lensar, INC. | $340.69 | 2019-2022 | |
| Rxsight INC | $186.64 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $168.13 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $121.85 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Abbott Laboratories | $96.03 | 2019-2020 | |
| Halozyme INC | $79.61 | 2019-2023 | |
| Abbvie INC. | $34.31 | 2024 | |
| Allergan, INC. | $21.30 | 2019 | |
| Omeros Corporation | $19.34 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.22 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.